Fiera Capital Corp Reduces Stock Position in argenx SE (NASDAQ:ARGX)

Fiera Capital Corp cut its holdings in argenx SE (NASDAQ:ARGX) by 2.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 155,260 shares of the company’s stock after selling 3,093 shares during the period. Fiera Capital Corp owned 0.26% of argenx worth $95,485,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of ARGX. Advisors Preferred LLC bought a new position in shares of argenx in the fourth quarter worth $73,000. Cromwell Holdings LLC lifted its holdings in argenx by 73.3% during the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after purchasing an additional 66 shares in the last quarter. GAMMA Investing LLC boosted its stake in argenx by 44.8% in the 4th quarter. GAMMA Investing LLC now owns 252 shares of the company’s stock worth $155,000 after purchasing an additional 78 shares during the period. Blue Trust Inc. grew its holdings in argenx by 413.9% during the 3rd quarter. Blue Trust Inc. now owns 370 shares of the company’s stock valued at $201,000 after buying an additional 298 shares in the last quarter. Finally, Keudell Morrison Wealth Management bought a new stake in shares of argenx during the third quarter valued at about $207,000. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ARGX. Evercore ISI raised their price objective on shares of argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. Oppenheimer reissued an “outperform” rating and issued a $675.00 price target (up from $646.00) on shares of argenx in a report on Thursday, November 21st. JPMorgan Chase & Co. upped their price target on shares of argenx from $640.00 to $670.00 and gave the stock an “overweight” rating in a report on Monday, November 4th. Scotiabank raised argenx from a “sector perform” rating to a “sector outperform” rating and lifted their price objective for the company from $439.00 to $715.00 in a research note on Tuesday, November 5th. Finally, HC Wainwright restated a “buy” rating and set a $717.00 target price (up from $670.00) on shares of argenx in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $658.39.

argenx Stock Up 2.1 %

Shares of NASDAQ:ARGX opened at $649.09 on Thursday. The stock has a market cap of $39.44 billion, a PE ratio of -737.60 and a beta of 0.58. The company’s fifty day moving average is $638.76 and its 200 day moving average is $580.34. argenx SE has a 52 week low of $349.86 and a 52 week high of $678.21.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.